A cohort study examining predictors of stroke and bleeding among people with congenital heart disease and atrial fibrillation
Molly O’Shea(Mayo Clinic Hospital), Hicham El Masry(Mayo Clinic Hospital), Amna Ibrahim(Beni-Suef University), Andrew Bacon(Mayo Clinic Hospital), Matthew Van Ligten(Mayo Clinic Hospital), Catherine H. Marshall(Mayo Clinic Hospital), Wen‐Yen Wang(Mayo Clinic Hospital), Omar Baqal(Mayo Clinic Hospital), Suganya Arunachalam Karikalan(Mayo Clinic Hospital), David Majdalany(Mayo Clinic Hospital), Alexander C. Egbe(Mayo Clinic), Sandhya Ravi(Mayo Clinic Hospital), Penelope Smyth(University of Alberta), Nneoma Alozie(Mayo Clinic Hospital), Marlene Girardo(Mayo Clinic Hospital)
Cited by 1
Related Papers
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline <i>BRCA</i>-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
|Clinical Cancer Research|2015|532
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer
|Clinical Cancer Research|2015|377
FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
|Clinical Cancer Research|2014|350
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody
|Journal of Clinical Oncology|2019|348